Post by
Noteable on Sep 12, 2022 10:42am
ESMO 2022: Transgene confirms IV delivery of OV in Phase 1
https://www.biospace.com/article/releases/transgene-confirms-the-potential-of-the-intravenous-route-of-its-invir-io-oncolytic-viruses-against-solid-tumors-with-tg6002-phase-i-data-presented-at-esmo-congress-2022-/
Comment by
Noteable on Sep 12, 2022 10:50am
Transgene's findings further confirms that ONCY's intravenous (IV) delivery of pelareorep is a safe and effective way to deliver the oncolytic virus to various tumors.